Connect 1906 Phase 2 trial of a novel peptide vaccine (PEP-CMV) targeting CMV antigen for newly diagnosed pediatric high-grade glioma and diffuse intrinsic pontine glioma and recurrent medulloblastoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Research Institute at Nationwide Children's Hospital
Start Date
June 12, 2024
End Date
June 11, 2025
Administered By
Duke Cancer Institute
Awarded By
Research Institute at Nationwide Children's Hospital
Start Date
June 12, 2024
End Date
June 11, 2025